Advertisement

Identifying Clinicopathological Association of DNA Hypermethylation in Cancers Using CpG Island Microarrays

  • Susan H. Wei
  • Timothy T. -C. Yip
  • Chuan-Mu Chen
  • Tim H. -M. Huang
Chapter
Part of the Medical Intelligence Unit book series (MIUN)

Abstract

Hypermethylation of promoter CpG islands has been associated with gene silencing in cancer. Increasingly, these CpG islands have potential clinical utility as molecular markers for cancer diagnosis. Here we describe a microarray-based technique, called differential methylation hybridization (DMH), for simultaneous screening of methylation alteration across thousands of CpG island loci in one tumor sample at a time. We also describe a second approach, called methylation target array (MTA), for detecting methylation alteration of a single CpG island locus across hundreds of tumor DNA samples. The DMH and MTA assays are complementary to each other in that DMH allows for rapid identification of multiple loci hypermethylated in tumor genomes while MTA can rapidly assess the utility of these loci as markers for clinical diagnosis. Furthermore, the use of clustering algorithms to analyze the array data of multiple CpG island loci can identify an association of DNA hypermethylation with specific clinicopathological features of tumors.

Keywords

Promoter Hypermethylation Methylation Profile Restriction Landmark Genomic Scanning Differential Methylation Hybridization Concurrent Methylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163–167.PubMedCrossRefGoogle Scholar
  2. 2.
    Baylin SB, Esteller M, Rountree MR et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10:687–692.PubMedCrossRefGoogle Scholar
  3. 3.
    Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001; 98:392–394.PubMedCrossRefGoogle Scholar
  4. 4.
    Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20:3139–3155.PubMedCrossRefGoogle Scholar
  5. 5.
    Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38:285–303.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim DH, Nelson HH, Wiencke JK et al. Promoter methylation of DAP-kinase: association with advanced stage in nonsmall cell lung cancer. Oncogene 2001; 20:1765–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Strathdee G, MacKean MJ, Illand M et al. A role for methylation of the hMLHl promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999:18:2335–2341.PubMedCrossRefGoogle Scholar
  8. 8.
    Nosaka K, Maeda M, Tamiya S et al. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res 2000; 60:1043–8.PubMedGoogle Scholar
  9. 9.
    Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Eng J Med 2000; 343:1350–4.CrossRefGoogle Scholar
  10. 10.
    Tang X, Khuri FR, Lee JJ et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I nonsmall-cell lung. J Natl Cancer Inst 2000; 92:1511–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2001; 60:892–5.Google Scholar
  12. 12.
    Roman-Gomez J, Castillejo JA, Jimenez A et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21CIP/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99:2291–2296.PubMedCrossRefGoogle Scholar
  13. 13.
    Niwa Y, Oyama T, Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 2000; 91:519–526.PubMedGoogle Scholar
  14. 14.
    Nass SJ, Herman JG, Gabrielson E et al. Aberrant methylation of the estrogen receptor and E-caderin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000; 60:4346–4368.PubMedGoogle Scholar
  15. 15.
    Kim DH, Nelson HH, Wiencke JK et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in nonsmall cell lung cancer. Cancer Res 2001; 61:3419–3424.PubMedGoogle Scholar
  16. 16.
    Belinsky SA, Nikulua KJ, Palmisano WA et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95:11891–11896.PubMedCrossRefGoogle Scholar
  17. 17.
    Issa JPJ, Zehnbauer BA, Kaufmann SH et al. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997; 57:1678–1681.PubMedGoogle Scholar
  18. 18.
    Eads CA, Lord RV, Kurumboor SK et al. Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Cancer Res 2000; 60:5021–5026.PubMedGoogle Scholar
  19. 19.
    Eads CA, Lord RV, Wickramasinghe K et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61:3410–3418.PubMedGoogle Scholar
  20. 20.
    Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61:8659–8663.PubMedGoogle Scholar
  21. 21.
    Issa JPJ, Ahuja N, Toyota M et al. Acclerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61:3573–3577.PubMedGoogle Scholar
  22. 22.
    Virmani AK, Muller C, Rathi A et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001; 7:584–589.PubMedGoogle Scholar
  23. 23.
    Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profile in human cancer. Cancer Res 2001; 61:3225–3229.PubMedGoogle Scholar
  24. 24.
    Strathdee G, Appleton K, Illand M et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158:1121–1127.PubMedGoogle Scholar
  25. 25.
    Huang T H-M, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999; 8:459–470.PubMedCrossRefGoogle Scholar
  26. 26.
    Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has nonrandom and tumor-type-specific patterns. Nat Genet 2000; 25:132–138.CrossRefGoogle Scholar
  27. 27.
    Gonzalgo ML, Liang G, Spruck CH et al. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 1997; 57:594–599.PubMedGoogle Scholar
  28. 28.
    Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28:e32.PubMedCrossRefGoogle Scholar
  29. 29.
    Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59:2307–2312.PubMedGoogle Scholar
  30. 30.
    Costello J, Plass C, Cavenee WK. Restriction landmark genomic scanning. In: Mills KI, Ransahoye BH, eds. DNA Methylation Protocols. Totowa: Humana Press, 2002:53–70.CrossRefGoogle Scholar
  31. 31.
    Adorjan P, Distler J, Lipscher E et al. Tumor class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acid Res 2002; 30:e21.PubMedCrossRefGoogle Scholar
  32. 32.
    DNA Methylation Protocols. Mills KI, Ransahoye BH, eds. Totowa: Humana Press, 2002.Google Scholar
  33. 33.
    Yan PS, Chen C-M, Shi H et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 2001; 61:8375–8380.PubMedGoogle Scholar
  34. 34.
    Chen C-M, Chen H-L, Yan PS et al. Methylation “tissue” array: a novel technique for simultaneous analysis of extensive DNA hypermethylation in multiple breast tumors. Proc Am Asso Cancer Res 2002; 43:1124a.Google Scholar
  35. 35.
    Shiraishi M, Lerman L, Seyika T. Preferential isolation of DNA fragments associated with CpG islands. Proc Natl Acad Sci USA 1995; 92:4229–4233.PubMedCrossRefGoogle Scholar
  36. 36.
    Cross SH, Charlton JA, Nan X et al. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994; 6:236–244.PubMedCrossRefGoogle Scholar
  37. 37.
    Yan PS, Wei SH, Huang TM-H. Differential methylation hybridization using CpG island arrays. In: Mills KI, Ransahoye BH, eds. DNA Methylation Protocols Totowa: Humana Press, 2002:87–100.CrossRefGoogle Scholar
  38. 38.
    Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863–14868.PubMedCrossRefGoogle Scholar
  39. 39.
    Tamayo P, Slonim D, Mesirov J et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96:2907–2912.PubMedCrossRefGoogle Scholar
  40. 40.
    Warnecke PM, Mann JR, Frommer M et al. Bisulfite sequencing in preimplantation embryos: DNA methylation profile of the upstream region of the mouse imprinted H19 gene. Genomics 1998; 51:182–190.PubMedCrossRefGoogle Scholar
  41. 41.
    Huang TH-M, Plass C, Liang G et al. Epi meets genomics: Technologies for finding and reading the 5th base. In: Beck & Olek, eds. The Epigenome—Molecular Seek and Hide. Verlag-VCH Verlag Gm5H, 2002 (submitted).Google Scholar
  42. 42.
    Yan PS, Perry MR, Laux DE et al. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000; 1432:1432–1438.Google Scholar
  43. 43.
    Veugelers M, Cat BD, Muyldermans SY et al. Mutational analysis of the GPC3/CPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Hum Molec Genet 2000; 9:1321–1328.PubMedCrossRefGoogle Scholar
  44. 44.
    Ahluwalia A, Yan P, Hurteau JA et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001; 82:261–268.PubMedCrossRefGoogle Scholar
  45. 45.
    Wei SH, Chen C-M, Strathdee G et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; in pess.Google Scholar
  46. 46.
    Yan PS, Efferth T, Chen H-L et al. Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods, in press.Google Scholar
  47. 47.
    Toyota M, Ahuja N, Ohe-Toyota M et al. JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96-8681–8686.PubMedCrossRefGoogle Scholar
  48. 48.
    Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844–847.PubMedCrossRefGoogle Scholar
  49. 49.
    Widschwendter M, Jones PA. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res 2002; 8:17–21.PubMedGoogle Scholar

Copyright information

© Eurekah.com and Kluwer Academic/Plenum Publishers 2005

Authors and Affiliations

  • Susan H. Wei
    • 1
  • Timothy T. -C. Yip
    • 2
  • Chuan-Mu Chen
    • 3
  • Tim H. -M. Huang
    • 1
  1. 1.Department of Pathology and Anatomical Sciences Ellis Fischel Cancer CenterUniversity of Missouri School of MedicineColumbiaUSA
  2. 2.Department of Clinical OncologyQueen Elizabeth HospitalKowloon, Hong Kong
  3. 3.Department of ZoologyNational Chung Hsing UniversityTaiwan, Republic of China

Personalised recommendations